Life science firm Jubilant & Sanofi collaborate on CNS therapeutics
Category: #health  By Mateen Dalal  Date: 2019-02-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Life science firm Jubilant & Sanofi collaborate on CNS therapeutics

Jubilant will deliver Sanofi drug discovery services with its integrated drug discovery platform.

The Bengaluru-based arm of the reputed Jubilant Life Sciences, Jubilant Biosys, has apparently declared that it has signed an integrated drug discovery collaboration with pharmaceutical company. Credible reports cite that the collaboration will focus on the domain of CNS therapeutics.

As per sources familiar with the matter, the debut collaboration with Sanofi had commenced back in 2016, targeted toward the discovery and development of small molecule inhibitors for numerous targets in metabolic disorders therapeutics.

An official press release from Jubilant Biosys claims that the collaboration in question is basically aimed to discover therapeutic small molecules which will be addressing unmet needs in neurological diseases. Jubilant Biosys reportedly, will be providing Sanofi drug discovery services with its integrated drug discovery platform in a bid to identify lead candidates.

Rita Balice-Gordon, Global Head, Rare and Neurologic Diseases Therapeutic Area, Sanofi, has been reported to state that the company has been earnestly looking forward to collaborating with Jubilant. The new partnership aptly demonstrates Sanofi’s dedicated commitment toward striving to discover novel medicines which can target neurological diseases, the needs of which are currently unmet around the globe, Balice-Gordon elaborates.

Speaking on the partnership, Marcel Velterop, President, Jubilant Drug Discovery Services & CDMO, claimed that the company is rather privileged and delighted to have been selected once more by Sanofi in order to contribute toward driving innovation to the clinic. The current achievement is undeniably testifies the high quality science and capability that Jubilant has built since the past decade, says Velterop, adding that the collaboration is perfectly aligned with Jubilant’s growth strategy and the company is totally committed to expand its world-class integrated, drug discovery capabilities.

For the record, Jubilant Biosys boasts of having depicted considerable expertise in numerous therapeutic domains, inclusive of Metabolic Disorders, Pain & Inflammation, CNS, Oncology, and many more.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...